OncologyManagement of liver metastases: new horizons for biologically based therapy
Introduction
The liver is a common site of metastatic disease, due to both anatomical and biological (“seed/soil”) factors relating to its complex metabolic and immunological functions. While many malignancies may eventually spread to the liver as part of a widely metastatic pattern, isolated colorectal metastases have been the focus of much attention and are sometimes curable. In this article we review the outcomes and limitations of the current clinical management of colorectal liver metastases. We then analyze the biology of the metastatic process with particular attention to the effects of partial hepatectomy. Upon this foundation, we then review novel biological strategies that are being developed for the treatment of patients with colorectal cancer metastatic to the liver.
Section snippets
Clinical management of colorectal liver metastases
Colorectal cancer is the third most common malignancy in the United States with 128,400 new cases and 56,600 deaths in 1999 [1]. Prognosis for patients with metastatic disease in the liver is limited. Jaffe [2] found a median survival of 5 months with no 5-year survivors in a retrospective analysis of 177 patients with colorectal metastases. Bengtsson found a median survival of 4.5 months after studying a cohort of patients that were found to have liver metastases at the time of colonic
Biology of colorectal liver metastasis
Although the genetic basis of tumorigenesis may vary greatly between different cancer types, the cellular and molecular steps required for metastasis are similar for all cancer cells. The molecular mechanisms that promote invasive growth and metastasis are also found in embryonic development, and to a lesser extent, in the repair processes of adult tissues. Metastasis is a selective, nonrandom, inefficient process consisting of a series of interrelated steps, with only 0.01% of circulating
Anti-angiogenesis agents
A growing number of anti-angiogenesis strategies have been investigated for the treatment of cancer and other angiogenesis-dependent diseases (Table 2). VEGF plays a central role in promoting angiogenesis and is the target of innovative anticancer therapies. Strategies developed for VEGF inhibition include preventing ligand-receptor interaction and blockade of signal transduction. Drugs that block endothelial cell signaling via VEGF and its receptor (VEGFR) that are currently being evaluated
Gene therapy
Gene therapy involves the transfer of genetic material into target cells. Although cancer gene therapy strategies are relatively new, they encompass a major part of this developing field. Various delivery systems are used to transfer the genetic material of interest into metastatic cells. Some of the systems include viral vectors, cationic liposomes, and protein-conjugated DNA. They are used to effect ex vivo or in vivo transfer.
Each vector system has distinct advantages and disadvantages in
Immunotherapy
In theory, immunotherapy is more appealing than chemotherapy because, when triggered appropriately, the immune system has the potential to scavenge the last tumor cell. In contrast, chemotherapy is limited by log-kill kinetics. Both monoclonal antibodies and cytokine-based cancer vaccines by themselves have shown promise for certain tumors; however, they have not yet been shown to be efficacious in patients with metastatic colorectal cancer.
Tumor cells may evade immune destruction by using
Summary
Currently, the only chance for cure in patients with colorectal liver metastases is surgical resection. Despite these encouraging results, only patients who have intrinsically favorable biology that limits spread of the disease are able to benefit from this therapy. In clinical practice, fewer than 10% of patients present with resectable disease, and only a third of resected patients enjoy long-term survival. These poor outcomes underscore the need for novel treatment strategies to manage this
References (87)
- et al.
Natural history of patients with untreated liver metastases from colorectal cancer
Am.J. Surg.
(1981) - et al.
Current treatment for colorectal cancer metastatic to the liver
Eur.J. Surg. Oncol.
(1999) IntegrinsBidirectional, allosteric signaling machines
Cell
(2002)- et al.
Role of calcium in E-selectin induced phenotype of T84 colon carcinoma cells
Biochem. Biophys. Res. Commun.
(2003) - et al.
Carcino embrionic antigen a human tumor marker, functions as an intercellular adhesion molecule
Cell
(1989) Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration
Curr. Biol.
(1997)- et al.
Preliminary report of tumor metastasis during liver regeneration after hepatic resection in rats
Eur. J. Surg. Oncol.
(1995) - et al.
The effect of partial hepatectomy on tumor growth in ratsIn vivo and in vitro studies
Hepatology
(1995) - et al.
Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor beta 1
Exp. Cell. Res.
(1989) - et al.
Growth stimulation of a human colorectal carcinoma cell line by interleukin-1 and -6 and antagonistic effects of transforming growth factor beta 1
Eur. J. Cancer
(1992)
Possible endocrine control by hepatocyte growth factor of liver regeneration after partial hepatectomy
Biochem. Biophys. Res. Commun.
Watson angiogenesis and hepatic colorectal metastasis
Surg. Oncol. Clin. N. Am.
Biology of colorectal liver metastasis
Surg. Oncol. Clin. N. Am.
p53 function and dysfunction
Cell
Viral oncolysis
Surg. Oncol. Clin. N. Am.
Cancer statistics, 1999
CA Cancer J. Clin.
Factors influencing survival in patients with untreated hepatic metastases
Surg.Gynecol. Obstet.
Surgical treatment of hepatic metastases from colorectal cancers
Arch. Surg.
Clinical score or predicting recurrence after hepatic resection for metastatic colorectal cancerAnalysis of 1001 consecutive cases
Ann. Surg.
Hepatic resection for metastases of the colon and rectum
Surg. Gynecol. Obstet.
Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection
Ann. Surg.
A new technique for hepatic artery infusion chemotherapy
Semin. Surg. Oncol.
Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long term survivors
Dis. Colon Rectum
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer
N. Engl. J. Med.
New approaches to the treatment of hepatic metastases. Radiofrequency ablation of malignant liver tumors
Ann. Surg. Oncol.
Quantitation of cell shedding into efferent blood vessels of mammary adeno carcinoma
Cancer Res.
Level of α-catenin expression in colorectal cancer correlates with invasiveness, metastatic potential and survival
J.Surg. Oncol.
Matrix metallo proteinases, they are just not for matrix anymore
Curr. Opin. Cell Biol.
The matrix metalloproteinases and their inhibitors
Am. J. Respir. Cell Mol. Biol.
Type IV collagenases in invasive tumors
Breast Cancer Res.Treat.
Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas
Br.J. Cancer
Cancer invasion and tissue remodeling—Cooperation of protease systems and cell types
Apmis
Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases
Jpn. J. Clin. Oncol.
Isolation of a tumor factor responsible or angiogenesis
J. Exp. Med.
Expression of vascular endothelial growth factor, mitogen-activated protein kinase and p53 in human colorectal cancer
Anticancer Res.
Expression of vascular endothelial growth factor and its receptor, KDR correlates with vascularity, metastasis, and proliferation of human colon cancer
Cancer Res.
The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer
Cancer Res.
The EGF receptor family as targets for cancer therapy
Oncogene
Biology of liver metastases
Metastatic colorectal cancer cells are resistant to anoikis, inducing Akt phosphorylation (A2162)
Am. Cancer Soc.
Experimental studies of factors influencing hepatic metastases II. Effect of partial hepatectomy
Cancer
Transplanted tumor growth and liver regeneration in the rat
J. Natl. Cancer Inst.
Alteration of tumor cell and hepatic parenchyma cell mitotic rates in tumor-injected partially hepatectomized mice
Cancer Res.
Cited by (7)
Effect of Liver Resection on the Progression and Growth of Rhabdomyosarcoma Metastases in a Rat Model
2008, Journal of Surgical ResearchCitation Excerpt :Because considerable advances have been made in surgical techniques and perioperative care, it is now possible to provide curative treatment of clearly localized clinical metastases through partial liver resection [1]. However, this surgical procedure is only potentially curative, since 65% of all patients who undergo resection of liver metastases experience recurrence within 5 y [2–4]. Two possible sources of liver tumor recurrence have been described, in particular the development of new metastatic lesions independent of the initial seed (multifocal origin) and the existence of clinically undetectable residual intrahepatic tumor cells in the remaining organ (monofocal origin) [4].
Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer
2010, Journal of Clinical OncologyEx Vivo evaluation of a bipolar application concept for radiofrequency ablation
2009, Anticancer ResearchH19 expression in hepatic metastases from a range of human carcinomas
2005, Journal of Clinical Pathology